CXCL12 and pancreatic neoplasm: Our retrospective analyses of the INT-11 trial consisting of 660 pancreatic cancer patients demonstrate that tipifarnib may sensitize PDAC to gemcitabine in a patient population stratified based on the absence of abdominal pain as a surrogate for high CXCL12 expression.